Skip to content

BioCryst Pharmaceuticals

US · BCRX #2766 by market cap Listed 1970
7.22 -0.10 -1.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM), BioMarin Pharmaceutical (BMRN) and BioCryst (BCRX)
    TipRanks · 2026/10/21
  • Company notice
    BioCryst Pharmaceuticals | 8-K: BioCryst Reports Third Quarter 2026 Financial Results
    SEC · 2026/11/4
  • Rating change
    Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16
    Market Newswire · 2026/9/9
  • Company notice
    BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
    SEC · 2026/9/3
  • Rating change
    J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13
    Market Newswire · 2026/9/30
  • Rating change
    Wedbush Cuts Price Target on BioCryst Pharmaceuticals to $18 From $20, Keeps Outperform Rating
    MT Newswires · 2026/10/19
  • Company notice
    BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
    SEC · 2026/9/3
  • Rating change
    TD Cowen Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/10/21
  • BioCryst Pharmaceuticals' Q3 Net Income, Revenue Rise; Increases 2026 Revenue Guidance
    MT Newswires · 2026/11/4
  • Company notice
    BioCryst Pharmaceuticals | SCHEDULE 13G: Others
    SEC · 2026/11/10
  • Rating change
    RBC Capital Downgrades BioCryst Pharmaceuticals(BCRX.US) to Hold Rating, Cuts Target Price to $11
    Market Newswire · 2026/9/10
  • Company notice
    BioCryst Pharmaceuticals | 10-Q: Q3 2026 Earnings Report
    SEC · 2026/11/5
  • Rating change
    Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $20
    Market Newswire · 2026/8/6
  • Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $17
    Market Newswire · 2026/11/5
  • Rating change
    BioCryst Pharmaceuticals Is Maintained at Neutral by JP Morgan
    Dow Jones · 2026/10/1
  • Rating change
    H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32
    Market Newswire · 2026/8/7
  • RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Maintains Target Price $11
    Market Newswire · 2026/11/5
  • Rating change
    BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15
    Market Newswire · 2026/10/9
  • Wedbush Adjusts BioCryst Pharmaceuticals PT to $17 From $18, Maintains Outperform Rating
    MT Newswires · 2026/11/5
  • Rating change
    RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13
    Market Newswire · 2026/8/6
  • Rating change
    Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating
    MT Newswires · 2026/8/6
  • RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Maintains Target Price $11
    Market Newswire · 2026/10/9
  • Rating change
    RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating
    MT Newswires · 2026/8/6
  • Company notice
    BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
    SEC · 2026/9/3
  • Company notice
    BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
    SEC · 2026/9/3

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

BioCryst Pharmaceuticals discussion 0 comments

Add a comment